Clinical trial
Open access
Aug 2026
The efficacy, immunogenicity and safety of the LZ901 vaccine for herpes zoster virus in adults 40 years of age or older: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
LZ901 reduces the risk of herpes zoster in adults who were 40 years of age or older in 12 months, with a favorable safety profile, and reports that the vaccine reduces the risk of viral infection and has favorable safety profiles.
Peng-Fei Jin, Ya-Ru Quan, Xue Gao et al.
· Nature Communications · 0 citations